These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18423804)

  • 1. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.
    Qian F; Rausch KM; Muratova O; Zhou H; Song G; Diouf A; Lambert L; Narum DL; Wu Y; Saul A; Miller LH; Long CA; Mullen GE
    Vaccine; 2008 May; 26(20):2521-7. PubMed ID: 18423804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.
    Qian F; Wu Y; Muratova O; Zhou H; Dobrescu G; Duggan P; Lynn L; Song G; Zhang Y; Reiter K; MacDonald N; Narum DL; Long CA; Miller LH; Saul A; Mullen GE
    Vaccine; 2007 May; 25(20):3923-33. PubMed ID: 17428587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen.
    Mullen GE; Aebig JA; Dobrescu G; Rausch K; Lambert L; Long CA; Miles AP; Saul A
    Vaccine; 2007 Jul; 25(29):5343-7. PubMed ID: 17566616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
    Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
    Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide.
    Mullen GE; Giersing BK; Ajose-Popoola O; Davis HL; Kothe C; Zhou H; Aebig J; Dobrescu G; Saul A; Long CA
    Vaccine; 2006 Mar; 24(14):2497-505. PubMed ID: 16434128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.
    Ellis RD; Mullen GE; Pierce M; Martin LB; Miura K; Fay MP; Long CA; Shaffer D; Saul A; Miller LH; Durbin AP
    Vaccine; 2009 Jun; 27(31):4104-9. PubMed ID: 19410624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.
    Sagara I; Ellis RD; Dicko A; Niambele MB; Kamate B; Guindo O; Sissoko MS; Fay MP; Guindo MA; Kante O; Saye R; Miura K; Long C; Mullen GE; Pierce M; Martin LB; Rausch K; Dolo A; Diallo DA; Miller LH; Doumbo OK
    Vaccine; 2009 Dec; 27(52):7292-8. PubMed ID: 19874925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.
    Coban C; Ishii KJ; Stowers AW; Keister DB; Klinman DM; Kumar N
    Infect Immun; 2004 Jan; 72(1):584-8. PubMed ID: 14688140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
    Mullen GE; Ellis RD; Miura K; Malkin E; Nolan C; Hay M; Fay MP; Saul A; Zhu D; Rausch K; Moretz S; Zhou H; Long CA; Miller LH; Treanor J
    PLoS One; 2008 Aug; 3(8):e2940. PubMed ID: 18698359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
    Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
    Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
    Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.
    Miura K; Zhou H; Diouf A; Moretz SE; Fay MP; Miller LH; Martin LB; Pierce MA; Ellis RD; Mullen GE; Long CA
    Clin Vaccine Immunol; 2009 Jul; 16(7):963-8. PubMed ID: 19439523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.
    Zhu D; McClellan H; Dai W; Gebregeorgis E; Kidwell MA; Aebig J; Rausch KM; Martin LB; Ellis RD; Miller L; Wu Y
    Vaccine; 2011 May; 29(20):3640-5. PubMed ID: 21440641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.
    Patra KP; Li F; Carter D; Gregory JA; Baga S; Reed SG; Mayfield SP; Vinetz JM
    Infect Immun; 2015 May; 83(5):1799-808. PubMed ID: 25690099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.
    Zhu D; Wu Y; McClellan H; Dai W; Rausch K; Jones D; Aebig J; Barnafo E; Butler B; Lambert L; Narum DL; Duffy PE
    Vaccine; 2017 May; 35(24):3232-3238. PubMed ID: 28479180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
    Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.
    Pirahmadi S; Zakeri S; Mehrizi AA; Djadid ND; Raz AA; Sani JJ
    Infect Immun; 2019 Jun; 87(6):. PubMed ID: 30936155
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.